Title(s):
S1703 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Investigator(s): Judy Tsai, MD
Contact Information: McDowell Cancer Research 330.344.6348

Title(s):
CCTG MA.39. A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Investigator(s): Praveen Pendyala, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
17013. Mammaprint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry)
Investigator(s): Laurie Matt-Amaral, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
SWOG 1501. Prospective evaluation of carvedilol in prevention of cardiac toxicity in patients with metastatic HER2 + breast cancer, phase III
Investigator(s): Judy Tsai, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
NRG-BR007. A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score ≤18 Breast Cancer
Investigator(s): Praveen Pendyala, MD
Contact Information: McDowell Cancer Research at 330.344.6348

Title(s):
CASE 5122 Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Shave Margins Using Savi Scout®
Investigator(s): Andrew Fenton, MD
Contact Information: McDowell Cancer Research 330.344.6348

Title(s):
MYGN1123 / MD01 / MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer
Investigator(s): Judy Tsai, MD
Contact Information: McDowell Cancer Research 330.344.6348

Title(s):
The PREDICT Registry: A Prospective Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast-Conserving Therapy
Investigator(s): Susan Hong, MD
Contact Information: McDowell Cancer Research 330.344.6348